Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

12.76 -0.11 (-0.85%)
Delayed Quote Updated: 10:49 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle ↗
The drug has faced two advisory committees and a delayed review date. 
Via Investor's Business Daily
News headline image
Biohaven's ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months ↗
Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN) announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).  
Via Benzinga
News headline image
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test ↗
Patients didn't show any improvements in a study meant to test multiple drugs. 
Via Investor's Business Daily
Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Rise Above Previous 52-Week High
Via Investor Brand Network
Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Exceed 52-Week High
Via Investor Brand Network
News headline image
Stocks That Hit 52-Week Highs On Friday ↗
  On Friday, 5 companies hit new 52-week highs. 
Via Benzinga
News headline image
Recap: Biohaven Pharma Hldgs Q2 Earnings ↗
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study ↗
 
Via Benzinga
Watch for Continued Gains in Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Via Investor Brand Network
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
Is Viatris Inc. a Contrarian Dividend Option for Your Portfolio?
Does kicking against market trends make you even more excited about investing? If so, you may want to consider drugmaker Viatris Inc. (NASDAQ: VTRS), which produces products that treat diabetes,... 
Via MarketBeat
News headline image
Biohaven Pharmaceutical's Return On Capital Employed Overview ↗
Benzinga Pro data, Biohaven Pharmaceutical (NYSE:BHVN) reported Q2 sales of $215.08 million. Earnings fell to a loss of $441.88 million, resulting in a 278.01% decrease from last quarter. 
Via Benzinga
News headline image
$5.6 Million Bet On This Healthcare Stock? 3 Stocks Insiders Are Buying ↗
Although US stocks closed sharply lower on Monday, there were a few notable insider trades. 
Via Benzinga
News headline image
Freedom Biosciences Gets $10.5M In Seed Financing For Psychedelics Research, This Is What We Know ↗
Freedom Biosciences achieved a major $10.5 million in a seed financing round in which MBX Capital, PsyMed Ventures, Village Global and The Yale Startup, among others, participated. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal ↗
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT). 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗
  
Via Benzinga
News headline image
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
News headline image
The 3 Best Market Sectors for the Second Half of 2022 ↗
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into. 
Via InvestorPlace
News headline image
Which Coronavirus Stock Could Fetch Higher Returns? ↗
This article will compare Pfizer, Moderna, and Novavax to see which of these coronavirus stocks will yield the highest returns. 
Via InvestorPlace
News headline image
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
From Global Coalition for Adaptive Research
Via Business Wire
News headline image
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit? ↗
The FDA's advisors recently backed Pfizer's Covid shot for young children. 
Via Investor's Business Daily
News headline image
Hopeful Golden Cross Forms On Biohaven Pharma Hldgs's Chart ↗
If history is any guide, there may be good fortune ahead for shares of Biohaven Pharma Hldgs (NYSE:BHVN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish... 
Via Benzinga
News headline image
Looking Into Biohaven Pharmaceutical's Return On Capital Employed ↗
According to data from Benzinga Pro, during Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $318.85 million. Despite a 41.43% increase in earnings, the company posted a loss of $116.90... 
Via Benzinga
News headline image
3 Biotech Stocks to Buy Before They Boom ↗
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
News headline image
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way ↗
The company is planning to soon ask for FDA approval of etrasimod in ulcerative colitis. 
Via Investor's Business Daily
News headline image
BIOHAVEN INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
News headline image
Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review ↗
Elon Musk put his Twitter deal "on hold" but says he's "still committed" to it. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.